CompletedNCT05024747
A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers
Medication studyAges 21–55United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 21 years to 55 years.
- Listed locations
- SpringfieldSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: September 1, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 22
- Sponsor
- HALEON
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 21 Years to 55 Years
- Official registry ID
- NCT05024747
- Official title
Show the full official title
A Randomized, Open Label, Single Center, Single Dose, Two Period, Two Sequence Crossover Bioequivalence Study of 21 mg Nicotine Transdermal Patches (NicoDerm CQ, GSK Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers
Get this study by email
Recruitment & locations
CompletedSpringfield
Questions about this study
Who is behind this study?
The study sponsor is HALEON.
Did this study involve medication?
Yes. The study involved medication, including NicoDerm CQ patch (GSK Dungarvan) and NicoDerm CQ (Alza).
Who was this study for?
Listed age limits: 21 years to 55 years.
